Efficacy and safety of adalimumab (HUMIRA®) in European clinical practice:: The react trial

被引：0
|
作者：
Burmester, GR
Sáez, IM
Malaise, M
da Silva, JC
Webber, DG
Kupper, H
机构：
[1] Humboldt Univ, Univ Klinikum Charite, Berlin, Germany
[2] HGU Gregorio Maranon, Madrid, Spain
[3] CHU, Liege, Belgium
[4] Hosp Garcia Orta, Serv Reumatol, Almada, Portugal
[5] Abbott GmbH & Co KG, Immunosci, Ludwigshafen, Germany
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2004年 / 63卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：90 / 90
页数：1
相关论文
共 50 条
  • [21] Efficacy and safety of adalimumab in the treatment of Rheumatoid Arthritis (RA) in real-life clinical practice: 1-year-results of the react study
    Burmester, G. R.
    Wordsworth, P.
    Saez, I. Monteagudo
    Malaise, M. G.
    Kary, S.
    Kupper, H.
    RHEUMATOLOGY, 2006, 45 : I43 - I43
  • [22] Adalimumab (HUMIRA®) is as effective when used with other concomitant DMARDs as when used with methotrexate in treating rheumatoid arthritis in widespread clinical practice:: The react study
    Mariette, X
    Bijlsma, JWJ
    Herold, M
    Unnebrink, K
    Kupper, H
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 424 - 424
  • [23] Long-term efficacy, remission, and safety of adalimumab (HUMIRA®) plus methotrexate in patients with rheumatoid arthritis in the ARMADA trial.
    Weinblatt, ME
    Keystone, EC
    Furst, DE
    Kavanaugh, AF
    Chartash, EK
    Segurado, OG
    ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S563 - S563
  • [24] Adalimumab (Humira®) is effective and safe in treating rheumatoid arthritis (RA) in real-life clinical practice:: Final summary of the 6610 patients in the react study
    Burmester, G. R.
    Saez, I. Monteaguclo
    Fardellone, P.
    Montecucco, C. M.
    Nash, P.
    Katy, S.
    Kupper, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 181 - 181
  • [25] Efficacy and safety of adalimumab when used in combination with commonly used DMARDs in Rheumatoid Arthritis (RA) in real-life clinical practice: 12-week results of the react trial
    Mariette, X.
    McKenna, F.
    Bijlsma, J.
    Herold, M.
    Oezer, U.
    Kupper, H.
    RHEUMATOLOGY, 2006, 45 : I43 - I44
  • [26] Long-term safety of adalimumab (humira®) in worldwide rheumatoid arthritis clinical trials
    Schiff, MH
    Burmester, GR
    Pangan, A
    Kupper, H
    Spencer-Green, GT
    RHEUMATOLOGY, 2005, 44 : I70 - I71
  • [27] Adalimumab (Humira®) is effective in treating patients with psoriatic arthritis (PSA) in real-life clinical practice:: Results of the stereo trial
    van den Bosch, F.
    Manger, B.
    Goupille, P.
    McHugh, N.
    Roedevand, E.
    Holck, P.
    van Vollenhoven, R.
    Leirisalo-Repo, M.
    FitzGerald, O.
    Frank, C.
    Kron, M.
    Frank, M.
    Kupper, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 98 - 98
  • [28] Adalimumab (HUMIRA®) is effective and safe in treating rheumatoid arthritis (RA) in real-life clinical practice:: 1-year-results of the ReAct study.
    Burmester, GR
    Sáez, IM
    Malaise, MG
    Kary, S
    Kupper, H
    ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S541 - S542
  • [29] Efficacy and Safety of Adalimumab in Ulcerative Colitis Refractory to Conventional Therapy in Routine Clinical Practice
    Balint, Anita
    Farkas, Klaudia
    Palatka, Karoly
    Lakner, Lilla
    Miheller, Pal
    Racz, Istvan
    Hegede, Gabor
    Vincze, Aron
    Horvath, Gabor
    Szabo, Andrea
    Nagy, Ferenc
    Szepes, Zoltan
    Gabor, Zoltan
    Zsigmond, Ferenc
    Zsori, Agnes
    Juhasz, Mark
    Csontos, Agnes
    Szucs, Monika
    Bor, Renata
    Milassin, Agnes
    Rutka, Mariann
    Molnar, Tamas
    JOURNAL OF CROHNS & COLITIS, 2016, 10 (01): : 26 - 30
  • [30] Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis: A Multicenter, Randomized, Double-Blind, Parallel, Phase III Clinical Trial
    Jinmei Su
    Mengtao Li
    Lan He
    Dongbao Zhao
    Weiguo Wan
    Yi Liu
    Jianhua Xu
    Jian Xu
    Huaxiang Liu
    Lindi Jiang
    Huaxiang Wu
    Xiaoxia Zuo
    Cibo Huang
    Xiumei Liu
    Fen Li
    Zhiyi Zhang
    Xiangyuan Liu
    Lingli Dong
    Tianwang Li
    Haiying Chen
    Jingyang Li
    Dongyi He
    Xin Lu
    Anbin Huang
    Yi Tao
    Yanyan Wang
    Zhuoli Zhang
    Wei Wei
    Xiaofeng Li
    Xiaofeng Zeng
    BioDrugs, 2020, 34 : 381 - 393
12345